SINGLE-AF Trial Evaluates DOACs in Intermediate Stroke Risk Atrial Fibrillation Patients
The SINGLE-AF trial is assessing the efficacy of direct oral anticoagulants in patients with atrial fibrillation at intermediate stroke risk.
Phase III
Cardiology / Anticoagulation
Status
Active
Signal Score
8.4
Signal assessment
Signal strength
high
Confidence level
high
Why it matters
The SINGLE-AF trial is pivotal in assessing the efficacy of DOACs for patients with intermediate stroke risk, a previously underrepresented group in anticoagulation therapy. Positive results could significantly shift treatment guidelines and enhance the market position of DOACs, impacting overall sales and competitive dynamics in the anticoagulant sector.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results and publication of findings, particularly regarding the primary endpoint of adverse clinical events.
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.